文献速递前列腺癌

他汀使用与雄激素剥夺治疗后前列腺癌预后的队列研究

Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-03-31

该研究基于芬兰前列腺癌筛查随机研究人群中的8253例前列腺癌患者,限定4428例在随访期间启动ADT的男性,评估他汀使用对ADT后前列腺癌预后的影响。中位随访6.3年,ADT后他汀使用与PSA复发风险降低(HR 0.73,95%CI 0.65-0.82)及前列腺癌死亡风险降低(HR 0.82,95%CI 0.69-0.96)相关;而ADT前或ADT第一年他汀使用与前列腺癌死亡无关。

要点

  • ADT启动后使用他汀与PSA复发风险降低相关(HR 0.73,95%CI 0.65-0.82)。
  • ADT启动后使用他汀与前列腺癌死亡风险降低相关(HR 0.82,95%CI 0.69-0.96)。
  • ADT前或ADT第一年他汀使用与前列腺癌死亡无关,且无剂量依赖性。

核心结论

  • ADT启动后使用他汀与前列腺癌预后改善相关,而ADT前使用他汀无此关联。

研究设计与样本

  • 基于芬兰前列腺癌筛查随机研究人群的队列研究,纳入8253例前列腺癌患者,限定4428例随访期间启动ADT的男性。
  • 采用Cox比例回归模型校正肿瘤临床特征和合并症,估计ADT启动后PSA复发和前列腺癌死亡的风险比。

主要发现

  • 中位随访6.3年,研究队列中共发生834例前列腺癌死亡和1565例PSA复发。
  • ADT后他汀使用与PSA复发风险降低相关(HR 0.73,95%CI 0.65-0.82)。
  • ADT后他汀使用与前列腺癌死亡风险降低相关(HR 0.82,95%CI 0.69-0.96)。
  • 以一年滞后定义的他汀使用(HR 0.89,95%CI 0.76-1.04)、ADT前他汀使用(HR 1.12,95%CI 0.96-1.31)及ADT第一年他汀使用(HR 1.02,95%CI 0.85-1.24)均与前列腺癌死亡无关,且无剂量依赖性。

临床怎么用

  • 对于启动ADT的前列腺癌患者,ADT后使用他汀可能与更好的预后相关,但需结合个体情况评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Statins' cholesterol-lowering efficacy is well-known. Recent epidemiological studies have found that inhibition of cholesterol synthesis may have beneficial effects on prostate cancer (PCa) patients, especially patients treated with androgen deprivation therapy (ADT). We evaluated statins' effect on prostate cancer prognosis among patients treated with ADT. MATERIALS AND METHODS: Our study population consisted of 8253 PCa patients detected among the study population of the Finnish randomized study of screening for prostate cancer. These were limited to 4428 men who initiated ADT during the follow-up. Cox proportional regression model adjusted for tumor clinical characteristics and comorbidities was used to estimate hazard ratios for risk of PSA relapse after ADT initiation and prostate cancer death. RESULTS: During the median follow-up of 6.3 years after the ADT initiation, there were 834 PCa deaths and 1565 PSA relapses in a study cohort. Statin use after ADT was associated with a decreased risk of PSA relapse (HR 0.73, 95% CI 0.65-0.82) and prostate cancer death (HR 0.82; 95% CI 0.69-0.96). In contrast, statin use defined with a one-year lag (HR 0.89, 95% CI 0.76-1.04), statin use before ADT initiation (HR 1.12, 95% CI 0.96-1.31), and use in the first year on ADT (HR 1.02, 95% CI 0.85-1.24) were not associated with prostate cancer death, without dose dependency. CONCLUSION: Statin use after initiation of ADT, but not before, was associated with improved prostate cancer prognosis.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Peltomaa AI, Raittinen P, Talala K, et al. Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study. Prostate Cancer Prostatic Dis. 2021. PMID: 33790420. doi:10.1038/s41391-021-00351-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。